Burning Rock’s ctDNA platforms enable real-time assessment of tumor dynamics and molecular evolution, empowering more precise and adaptive clinical development strategies

• Through both tumor-informed and tumor-naïve MRD assays, Burning Rock provides robust solutions for residual disease detection and translational research in solid tumors
• With MRD already accepted as an endpoint in hematologic malignancies, emerging data from solid tumors may soon position ctDNA-based MRD as a surrogate endpoint to accelerate oncology trials